Similarly, Tα1 proved effective in the subpopulation of chronic hepatitis B patients that lack HBeAg when compared to IFNα, with the advantage to be well-tolerated (43), and arrested HBV replication and reduced lobular activity in 40% of patients in a subsequent randomized, controlled trial (44). Here, IFNA1 is linked to chronic hepatitis B virus infection.